8-K - NRx Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NRx Pharmaceuticals, Inc. filed a prospectus supplement on February 17, 2026, for an aggregate of $20,000,000 of common stock issuable under the At-The-Market Offering Agreement with H.C. Wainwright & Co., LLC, dated August 14, 2023, as amended. The filing includes the legal opinion of Cozen O’Connor confirming the validity of the shares.

Key Takeaways

1Filed prospectus supplement for $20,000,000 of common stock (par value $0.001 per share)

2Shares issuable under At-The-Market Offering Agreement dated August 14, 2023, amended April 4, 2025

3Sales agent: H.C. Wainwright & Co., LLC

4Registration Statement Form S-3 (File No. 333-288205), effective December 22, 2025

5Legal opinion by Cozen O’Connor filed as Exhibit 5.1

6Consent of Cozen O’Connor as Exhibit 23.1

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events. On February 17, 2026, NRx Pharmaceuticals, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) for an aggregate of $2

Other Event

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 5.1 Opinion of Cozen O’Connor. 23.1 Consent of Cozen O’Connor (contained in the opini

Exhibits Only

Exhibits (2)

5.1

EXHIBIT 5.1

8-K

FORM 8-K